BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 4033669)

  • 1. Macrophage-produced muramyl peptide contaminants as adjuvants in cell-transfer experiments.
    Westall FC; Root-Bernstein RS
    Mol Immunol; 1985 Apr; 22(4):505-6. PubMed ID: 4033669
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Heymer B; Finger H; Wirsing CH
    Z Immunitatsforsch Immunobiol; 1978 Oct; 155(1):87-92. PubMed ID: 706536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific binding sites of muroctasin on murine macrophages.
    Akasaki M; Masayasu H; Tsukada W; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):978-80. PubMed ID: 3190804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of the proliferative response of thymocytes to phytohemagglutinin by the muramyl dipeptide1.
    Iribe H; Koga T
    Cell Immunol; 1984 Oct; 88(1):9-15. PubMed ID: 6332683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of immunomodulatory properties of N-acetylmuramyl-L-alanyl-D-isoglutamine and N-acetylglucosaminyl-(beta 1----4)-N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Dozmorov IM; Kuzin II; Lutsan NI; Lutsenko GV; Prokhorova AL; Sapozhnikov AM; Andronova TM; Ivanov VT
    Biomed Sci; 1991; 2(6):651-8. PubMed ID: 1841635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
    Nagao S; Sato K; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific binding sites for muramyl peptides on murine macrophages.
    Silverman DH; Krueger JM; Karnovsky ML
    J Immunol; 1986 Mar; 136(6):2195-201. PubMed ID: 3950411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule.
    Chedid L; Carelli C; Audibert F
    J Reticuloendothel Soc; 1979 Dec; 26(Suppl):631-41. PubMed ID: 392087
    [No Abstract]   [Full Text] [Related]  

  • 9. Liposomes, muramyl dipeptide derivatives, and nontoxic lipid A derivatives as adjuvants for human malaria vaccines.
    Hui GS
    Am J Trop Med Hyg; 1994; 50(4 Suppl):41-51. PubMed ID: 8172331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of configuration of muramyl dipeptide glycoside bond and structure of glycoside aglycon on their capacity to stimulate production of interleukin-1 and tumor necrosis factor by macrophages.
    Kalyuzhin OV; Nelyubov MV; Kalyuzhina EV; Kuzovlev FN; Shkalev MV
    Bull Exp Biol Med; 2002 Sep; 134(3):281-3. PubMed ID: 12512003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake of muramyl dipeptide by alveolar macrophages in experimental hypersensitivity pneumonitis.
    Richerson HB; Adams P; Iwai Y; Barfknecht CF
    Am J Ind Med; 1990; 17(1):120. PubMed ID: 2305780
    [No Abstract]   [Full Text] [Related]  

  • 12. [Adjuvant activity and adjuvant arthritis].
    Tanaka A
    Kekkaku; 1980 Oct; 55(10):465-7. PubMed ID: 7230587
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant activity of some nonpyrogenic hydrophobic analogues of muramyl dipeptide in enhancing the primary humoral and cell mediated immune responses in guinea pig model.
    Saxena RP; Puri A; Saxena KC; Shukla R; Haq W; Rizvi SY; Kundu B; Mathur KB
    Indian J Exp Biol; 1991 Feb; 29(2):111-5. PubMed ID: 1869292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in purine metabolism in the macrophages of mice exposed to a new synthetic analog of muramyl dipeptide].
    UmanskiÄ­ VIu; TarakhovskiÄ­ AM; Andronova TM
    Biull Eksp Biol Med; 1985 Jun; 99(6):685-7. PubMed ID: 2990603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances concerning the use of muramyl dipeptide derivatives as vaccine potentiators.
    Audibert F; Chedid L
    Prog Clin Biol Res; 1980; 47():325-38. PubMed ID: 7010376
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential adjuvants for synthetic vaccines. I. Modulators of macrophage activation.
    Solange A
    Chem Phys Lipids; 1995 Jan; 75(1):51-8. PubMed ID: 7697782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-specific MIF-like activity induced by the synthetic immunoadjuvant: N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP).
    Adam A; Souvannavong V; Lederer E
    Biochem Biophys Res Commun; 1978 Nov; 85(2):684-90. PubMed ID: 367370
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparison of adjuvant activities of glucosaminyl-muramyl dipeptide and of the gene coding for granulocyte-macrophage colony-stimulating factor in DNA immunization against herpes simplex virus].
    Kozlov AIu; Klimova RR; Shingarova LN; Boldyreva EF; Nekrasova OV; Gur'ianova SV; Andronova TM; Novikov VV; Kushch AA
    Mol Biol (Mosk); 2005; 39(3):504-12. PubMed ID: 15981580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant polyarthritis. V. Induction by N-acetylmuramyl-L-alanyl-D-isoglutamine, the smallest peptide subunit of bacterial peptidoglycan.
    Chang YH; Pearson CM; Chedid L
    J Exp Med; 1981 Apr; 153(4):1021-6. PubMed ID: 6972989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further study on relationship of anti-tuberculous protection to lung granulomata produced by intravenous injections of synthetic 6-0-mycoloyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with or without specific antigens.
    Yamamoto K; Kato K; Kakinuma M; Okuyama H; Azuma I
    Immunology; 1982 Jun; 46(2):473-9. PubMed ID: 7044961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.